Clinical Trial: Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597733) titled 'Telitacicept for Refractory Chronic Inflammatory Demyelinating Polyneuropathy' on Nov. 17, 2025.

Brief Summary: This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of Telitacicept in patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP). Eligible patients will be randomly assigned to receive either conventional therapy alone or Telitacicept plus conventional therapy for 24 weeks. Efficacy will be assessed using CIDP-related clinical and functional measures, including the Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Inflammatory Rasch-built Overal...